Full history for every metric is available with a Kvantra account
Intercept Pharmaceuticals, Inc. (ICPT)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 131 | 180 | 252 | 313 | 363 | 286 | 318 |
| Operating profit | $m | -68 | -62 | |||||
| Net profit | $m | -360 | -309 | -391 | -324 | -145 | 115 | -59 |
| EPS reported | $ | 3.40 | -1.41 | |||||
| Operating cashflow per share | $ | -0.79 | -0.79 | |||||
| Capex per share | $ | 0.02 | 0.02 | |||||
| FCF per share | $ | -0.81 | -0.81 | |||||
| Free cash flow | $m | -27 | -63 | |||||
| Net debt | $m | -158 | -99 | |||||
| Book value equity | $m | 93 | 72 | |||||
| Book value per share | $ | 2.75 | 1.72 | |||||
| Number of shares | m | 33.84 | 41.79 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 3.64 | - | |||||
| P/B LTM | x | 4.49 | 11.06 | |||||
| P/S LTM | x | 1.46 | 2.50 | |||||
| P/FCF LTM | x | -15.30 | -12.65 | |||||
| EV/EBITDA LTM | x | -11.35 | -19.87 | |||||
| EV/Sales LTM | x | 2.45 | 2.19 | |||||
| Earnings Yield LTM | % | 27.47% | 17.92% | |||||
| FCF Yield | % | -6.54% | -7.91% | |||||
| Quality | ||||||||
| ROE | % | 123.74% | -253.45% | |||||
| ROIC | % | 10.37% | 10.37% | |||||
| Operating margin | % | -23.88% | -23.88% | |||||
| Gross margin | % | 99.66% | 99.66% | |||||
| FCF/Sales | % | -9.57% | -9.57% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -21.39% | -3.83% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.08 | -0.28 | |||||
| Net Debt/EBITDA | x | -4.57 | -4.57 | |||||
| EBIT/Net interest | x | -3.19 | -3.19 | |||||
| Net debt/market cap | % | -37.82% | -12.44% | |||||
| Net debt/Equity | x | -1.70 | -1.38 | |||||
| Gross debt/equity | x | 3.57 | 3.12 | |||||
Company overview
Intercept Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the advancement and market launch of therapies designed to treat progressive, non-viral liver conditions. Its operational reach spans the United States, Europe, and Canada. The company currently markets Ocaliva, a medication functioning as a farnesoid X receptor (FXR) agonist. This drug is approved for the treatment of primary biliary cholangitis (PBC) in adults, specifically when administered alongside ursodeoxycholic acid. Beyond its existing approved indications, Intercept is actively investigating Ocaliva's potential for additional uses, notably including nonalcoholic steatohepatitis (NASH). Concurrently, it is progressing other drug candidates through various clinical and preclinical stages of development. In a collaborative effort, the company holds a licensing agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. Intercept distributes its products through a dual approach, utilizing both its proprietary commercial organization and a network of external third-party distributors. The company was founded in 2002 and is headquartered in New York, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Intercept Pharmaceuticals, Inc. (ICPT)
Intercept Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the advancement and market launch of therapies designed to treat progressive, non-viral liver conditions. Its operational reach spans the United States, Europe, and Canada. The company currently markets Ocaliva, a medication functioning as a farnesoid X receptor (FXR) agonist. This drug is approved for the treatment of primary biliary cholangitis (PBC) in adults, specifically when administered alongside ursodeoxycholic acid. Beyond its existing approved indications, Intercept is actively investigating Ocaliva's potential for additional uses, notably including nonalcoholic steatohepatitis (NASH). Concurrently, it is progressing other drug candidates through various clinical and preclinical stages of development. In a collaborative effort, the company holds a licensing agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. Intercept distributes its products through a dual approach, utilizing both its proprietary commercial organization and a network of external third-party distributors. The company was founded in 2002 and is headquartered in New York, New York.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free